Physician profile
David Johnson
NPI 1851008544
$5,837.97
in general payments reported to CMS, 2019-2025
17 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,998 · 2024: $1,269 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,734 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,733.50 |
| Education | $104.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,311.02 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $643.69 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $621.38 | 2023-2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $487.40 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $463.45 | 2023-2024 | Ingrezza |
| Abbvie INC. | $380.74 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $349.55 | 2024-2025 | Qelbree |
| Lundbeck LLC | $307.68 | 2023-2025 | Abilify Asimtufii, Brintellix, Rexulti |
| Corium, LLC | $284.97 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $271.79 | 2023-2024 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $263.16 | 2023-2025 | Invega Sustenna, Spravato |
| Neos Therapeutics, LP | $166.63 | 2025 | Exxua |
| Almatica Pharma LLC | $161.70 | 2023-2025 | Loreev Xr, Gralise |
| E.R. Squibb & Sons, L.L.C. | $38.33 | 2025 | Cobenfy |
| Indivior INC. | $36.72 | 2023-2024 | Sublocade |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $26.96 | 2025 | Auvelity |
| Biogen, INC. | $22.80 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.